NEW YORK–(BUSINESS WIRE)–An investment consortium led by Signet Healthcare Partners, Bionpharma, Inc and GMS Capital Partners LLC today announced that it has formed Pharma Nobis, LLC (the “Company”) to acquire the contract manufacturing business of Fagron in the USA. This business unit, operating from a manufacturing facility in Texarkana, Texas, provides contract manufacturing and private label services to consumer healthcare companies and retailers in the United States. Fagron will retain a 20% interest in the Company. Todd Daviau, co-founder and former president and CEO of CoreRx, a leading pharmaceutical contract development and manufacturing company, has been named CEO of Pharma Nobis.
James Gale, Managing Director of Signet Healthcare Partners, said, “We are excited about the opportunity to invest in this company. Fagron has developed an exceptional company with a reputation as a cost competitive manufacturer with a high service rating. We and our financial partners will seek to leverage this capacity and support the management team of Pharma Nobis in growing their business.
Todd Daviau commented, “I appreciate the opportunity to work with Signet’s investment team again and am excited about this opportunity to take Pharma Nobis to the next level in manufacturing personal care products. We will seek to serve our customers through reliable service and innovation.
Along with the acquisition, the company announced that James Gale, Dr. Theron Odlaug, Yezan Haddadin and Andrew Pulido would join its board of directors, alongside Todd Daviau. Dr. Odlaug is an experienced pharmaceutical executive and a Signet Venture partner. Yezan Haddadin is the CEO of GMS Capital Partners LLC. Andrew Pulido is President of Fagron North America.
Troutman Pepper acted as legal counsel for the acquiring syndicate.
About Signet Healthcare Partners
Signet Healthcare Partners (“Signet”) is an established provider of growth capital for innovative healthcare companies. Signet invests in commercial-stage healthcare businesses that are either generating revenue or preparing for commercial launch. The company has primarily focused on the pharmaceutical sector and medical technology companies. Signet maintains a disciplined, yet flexible approach to investing. As an active investor, Signet partners closely with its companies to create their value, including facilitating business between portfolio companies. Over its 23-year history, Signet has developed a solid reputation and a track record of successful investments. Signet has raised four funds with total capital commitments of over $400 million and has invested in over 50 companies. For more information, visit www.signethealthcarepartners.com.
About GMS Capital Partners
GMS Capital Partners LLC is an investment management firm focused on sourcing, arranging and executing investments across various asset classes including private equity, venture capital, real estate and other alternative asset classes. Founded in 2017, the company is incorporated in Delaware and manages investments on behalf of its parent company, GMS Holdings. For more information, visit www.gmscap.com.
Bionpharma is a dynamic and fast-growing generic pharmaceutical company with a strong commercial portfolio and a portfolio of generic products in the United States. With offices in Princeton, NJ, and Raleigh, NC, Bionpharma is one of the largest suppliers of softgel capsules in the United States, with a presence in the prescription and over-the-counter market segments. Bionpharma focuses on R&D – to develop and market affordable generics by building strong and effective partnerships. More information about Bionpharma Inc. can be found at www.bionpharma.com.
Fagron is a leading global pharmaceutical compounding company focused on providing personalized medicines to hospitals, pharmacies, clinics and patients in 35 countries around the world.
The Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the symbol “FAGR”. The operational activities of Fagron are managed by the Dutch company Fagron BV, headquartered in Rotterdam. For more information, visit https://fagron.us/.